Recombinant Human PGLYRP4/PGRP-I beta Protein, CF
Recombinant Human PGLYRP4/PGRP-I beta Protein, CF Summary
Asp18-His373 with a C-terminal 6-His tag
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.|
|Reconstitution||Reconstitute at 500 μg/mL in sterile PBS.|
|Shipping||The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Background: PGLYRP4/PGRP-I beta
PGLYRP4, also known as PGRP-I beta, is a member of the peptidoglycan recognition protein family of innate immunity proteins (1, 2). Human PGLYRP4 is expressed in the skin, eyes, salivary glands, throat, tongue, esophagus, stomach, and intestine (3). Mature human PGLYRP4 contains two nonidentical PGRP domains, and it shares 77% and 74% amino acid sequence identity with mouse and rat PGLYRP4, respectively (1, 4). It is secreted as disulfide-linked homodimers and binds peptidoglycan (PGN) and PGN-containing Gram-positive bacteria (1, 3). PGLYRP4 is directly bactericidal against pathogenic and nonpathogenic Gram-positive bacteria, but not normal flora bacteria, suggesting that normal flora bacteria have developed resistance to this bactericidal mechanism (3, 5, 6). Its bactericidal activity requires physiological concentrations of Zn2+ (6). PGLYRP4 knockout mice are more sensitive to the development of experimental dermatitis and DSS-induced colitis than wild type mice (2, 7). In humans, PGLYRP4 single nucleotide polymorphisms have been associated with inflammatory bowel disease and increased Parkinson’s disease risk (8, 9).
- Liu, C. et al. (2001) J. Biol. Chem. 276:34686.
- Park, S.Y. et al. (2011) PLoS One 6:e24961.
- Lu, X. et al. (2006) J. Biol. Chem. 281:5895.
- Royet, J. and R. Dziarski (2007) Nat. Rev. Microbiol. 5:264.
- Tydell, C.C. et al. (2006) J. Immunol. 176:1154.
- Wang, M. et al. (2007) J. Immunol. 178:3116.
- Saha, S. et al. (2010) Cell Host Microbe 8:147.
- Zulfiqar, F. et al. (2013) PLoS One 8:e67393.
- Goldman, S.M. et al. (2014) Mov. Disord. 29:1171.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Human PGLYRP4/PGRP-I beta Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human PGLYRP4/PGRP-I beta Protein, CF and earn rewards!
Have you used Recombinant Human PGLYRP4/PGRP-I beta Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image